Jump to content

5-MeO-DPT: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→Legality: filled in 1 bare reference
Added bibcode. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors.
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Short description|Chemical compound}}
{{cs1 config|name-list-style=vanc}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
Line 54: Line 55:
| melting_high = 194
| melting_high = 194
}}
}}
'''5-MeO-DPT''' (also known as 5-[[methoxy]]-N,N-[[Propyl|Dipropyl]][[tryptamine]]), is a [[Psychedelic drug|psychedelic]] and [[entheogen]]ic [[designer drug]].<ref name="pmid6776558">{{cite journal | vauthors = Glennon RA, Young R, Rosecrans JA, Kallman MJ | title = Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities | journal = Psychopharmacology | volume = 68 | issue = 2 | pages = 155–8 | date = 1980 | pmid = 6776558 | doi = 10.1007/BF00432133 | s2cid = 1674481 }}</ref><ref>{{cite journal | vauthors = Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K | title = Identification and quantitative determination of 5-methoxy-N, N-di-n-propyltryptamine in urine by isotope dilution gas chromatography-mass spectrometry. | journal = Forensic Toxicology | date = June 2007 | volume = 25 | issue = 1 | pages = 1–7 | doi = 10.1007/s11419-006-0018-y | s2cid = 9906203 }}</ref><ref>{{cite journal | vauthors = Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H | title = Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry. | journal = Forensic Toxicology | date = January 2014 | volume = 32 | issue = 1 | pages = 154–61 | doi = 10.1007/s11419-013-0208-3 | s2cid = 25134125 }}</ref><ref name="pmid34026257">{{cite journal | vauthors = Pham DN, Chadeayne AR, Golen JA, Manke DR | title = 5-Meth-oxy-N,N-di-n-propyl-tryptamine (5-MeO-DPT): freebase and fumarate | journal = Acta Crystallographica Section E | volume = 77 | issue = Pt 5 | pages = 522–526 | date = May 2021 | pmid = 34026257 | pmc = 8100262 | doi = 10.1107/S2056989021003753 }}</ref>
'''5-MeO-DPT''' (also known as 5-[[methoxy]]-N,N-[[Propyl|Dipropyl]][[tryptamine]]), is a [[Psychedelic drug|psychedelic]] and [[entheogen]]ic [[designer drug]].<ref name="pmid6776558">{{cite journal | vauthors = Glennon RA, Young R, Rosecrans JA, Kallman MJ | title = Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities | journal = Psychopharmacology | volume = 68 | issue = 2 | pages = 155–8 | date = 1980 | pmid = 6776558 | doi = 10.1007/BF00432133 | s2cid = 1674481 }}</ref><ref>{{cite journal | vauthors = Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K | title = Identification and quantitative determination of 5-methoxy-N, N-di-n-propyltryptamine in urine by isotope dilution gas chromatography-mass spectrometry. | journal = Forensic Toxicology | date = June 2007 | volume = 25 | issue = 1 | pages = 1–7 | doi = 10.1007/s11419-006-0018-y | s2cid = 9906203 }}</ref><ref>{{cite journal | vauthors = Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H | title = Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry. | journal = Forensic Toxicology | date = January 2014 | volume = 32 | issue = 1 | pages = 154–61 | doi = 10.1007/s11419-013-0208-3 | s2cid = 25134125 }}</ref><ref name="pmid34026257">{{cite journal | vauthors = Pham DN, Chadeayne AR, Golen JA, Manke DR | title = 5-Meth-oxy-N,N-di-n-propyl-tryptamine (5-MeO-DPT): freebase and fumarate | journal = Acta Crystallographica Section E | volume = 77 | issue = Pt 5 | pages = 522–526 | date = May 2021 | pmid = 34026257 | pmc = 8100262 | doi = 10.1107/S2056989021003753 | bibcode = 2021AcCrE..77..522P }}</ref>


==Chemistry==
==Chemistry==

Revision as of 13:25, 14 January 2024

5-MeO-DPT
Legal status
Legal status
Identifiers
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H26N2O
Molar mass274.408 g·mol−1
3D model (JSmol)
Melting point193 to 194 °C (379 to 381 °F)
  • CCCN(CCC)CCc2c[nH]c1ccc(cc12)OC
  • InChI=1S/C17H26N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h6-7,12-13,18H,4-5,8-11H2,1-3H3 checkY
  • Key:PNHPVNBKLQWBKH-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

5-MeO-DPT (also known as 5-methoxy-N,N-Dipropyltryptamine), is a psychedelic and entheogenic designer drug.[1][2][3][4]

Chemistry

The full chemical name is N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine. It is classified as a tryptamine derivative.

Effects

Little is known about the subjective effects of 5-MeO-DPT, but the nature of the compound is probably comparable to 5-MeO-DiPT, 5-MeO-DMT, or DPT, which are also psychedelic tryptamines/indoles. However, the duration of the above-mentioned drugs vary considerably.

Dosage

5-MeO-DPT is orally active, with 3-10 mg representing a fully effective dosage for most users. Effects begin within three hours, and usually last 4 hours.

Legality

In the United States 5-MeO-DPT is considered a schedule 1 controlled substance as a positional isomer of 5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT)[5]

See also

References

  1. ^ Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980). "Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities". Psychopharmacology. 68 (2): 155–8. doi:10.1007/BF00432133. PMID 6776558. S2CID 1674481.
  2. ^ Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K (June 2007). "Identification and quantitative determination of 5-methoxy-N, N-di-n-propyltryptamine in urine by isotope dilution gas chromatography-mass spectrometry". Forensic Toxicology. 25 (1): 1–7. doi:10.1007/s11419-006-0018-y. S2CID 9906203.
  3. ^ Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H (January 2014). "Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry". Forensic Toxicology. 32 (1): 154–61. doi:10.1007/s11419-013-0208-3. S2CID 25134125.
  4. ^ Pham DN, Chadeayne AR, Golen JA, Manke DR (May 2021). "5-Meth-oxy-N,N-di-n-propyl-tryptamine (5-MeO-DPT): freebase and fumarate". Acta Crystallographica Section E. 77 (Pt 5): 522–526. Bibcode:2021AcCrE..77..522P. doi:10.1107/S2056989021003753. PMC 8100262. PMID 34026257.
  5. ^ "Lists of: Scheduling Actions Controlled Substances Regulated Chemicals" (PDF). U.S. Department of Justice. February 2023. Retrieved 5 March 2023.


Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=5-MeO-DPT&oldid=1195588872"